- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01481909
Study on Mastocytosis for Rupatadine Treatment (SMART)
Study on Mastocytosis for Rupatadine Treatment An Exploratory Phase IV, Randomised, Double-blind, Placebo Controlled Crossover Study to Assess the Efficacy of 20 mg Rupatadine on the Treatment of
Study title:
An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms.
Study code:
SMART-2010-1 Principal Investigator, Co-Investigator, sponsor, and study centre (acc. to § 40 Abs. 4 AMG) Dr. med. F. Siebenhaar, Prof. Dr. Med. M. Maurer, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Biometry and biostatistical analyses Division of Biostatistics and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Monitoring Coordination Centre for Clinical Studies (KKS), Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Clinical phase Phase II
Primary objective:
Reduction of wheal and flare type skin reaction after standardised provocation testing assessed by volumetric and thermographic measurements.
Secondary objectives:
Improvement of additional related symptoms (e.g. pruritus) and subjective affliction as assessed by symptom score, DLQI, Itchy-QoL and VAS.
Study design:
An exploratory, randomised, double-blind, placebo controlled crossover study
Type and number of patients:
Male and female patients (n = 30) with cutaneous mastocytosis and indolent systemic mastocytosis with skin involvement
Main criteria for inclusion:
Mastocytosis patients aged 18-65 years, signed written consent, no systemic corticosteroid or other immunosuppressive therapy, no permanent severe diseases Test product, dose and mode of administration 20 mg Rupatadine or placebo before provocation testing, oral administration (tablets)
Duration of treatment:
28 days (testing will be done at the day of last treatment)
Assessment of efficacy:
- Assessment of wheal and flare development by planimetric analyses of digital photographic, volumetric, and thermographic imaging (time lapse) before and after treatment with study medication,
- Additional assessment of symptoms,
- Assessment of life quality
Main criteria of evaluation:
Efficacy
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 10117
- University Charité
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement and a positive Darier's Sign
- Age between 18 and 65 years.
- Female patients must be using a highly effective method of birth control (such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, vasectomised partner), or they must be postmenopausal, surgically sterilised, or hysterectomised.
- Voluntarily signed written informed consent.
Exclusion Criteria:
- The presence of permanent severe diseases, especially those affecting the immune system, except for mastocytosis
- History or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia
- History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy, hyper-/hypokalemia, bradycardia < 50bpm, QTc interval > 440ms
- Evidence of severe renal dysfunction (creatinine > 1,5 x upper reference value)
- Evidence of significant hepatic disease (liver enzymes > 2 x upper reference value)
- History of adverse reactions to RUP, or other ingredients of the IMP
- Presence of active cancer which requires chemotherapy or radiation therapy
- Aggressive systemic mastocytosis
- History or presence of alcohol abuse or drug addiction
- Participation in any clinical trial within 4 weeks prior to enrolment
- Commitment to an institution in terms of § 40 Abs. 1 S. 3 Nr. 4 AMG
- Intake of antihistamines or leukotriene antagonists within 7 days prior to the beginning of the study
- Intake of oral corticosteroids within 14 days prior to the beginning of the study
- Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study
- Pregnancy or breast-feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar Pill
All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009).
Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent.
Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization).
All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
|
20 mg, 28 days over 60 days
Other Names:
|
Active Comparator: Rupafin
All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009).
Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent.
Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization).
All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.
|
20 mg, 28 days over 60 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pruritus
Time Frame: 10 weeks
|
Reduction of pruritus and wheal and flare type skin reaction after standardised provocation testing as assessed by volumetric and thermographic measurements.
|
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Questionaire
Time Frame: 10 weeks
|
Improvement of additional disease related symptoms and subjective affliction as measured by physician and patient global assessments, DLQI, Itchy-QoL and QoL(i)MaP*. *not validated questionnaire for mastocytosis symptoms |
10 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marcus Maurer, MD, University Berlin Charitè
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SMART-2010-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mastocytosis
-
University Hospital, ToulouseNot yet recruiting
-
Blueprint Medicines CorporationActive, not recruitingIndolent Systemic MastocytosisCanada, United States, Spain, United Kingdom, Germany, Belgium, Switzerland, Italy, Netherlands, Denmark, France, Norway, Sweden
-
AB ScienceRecruitingIndolent Systemic MastocytosisFrance, Netherlands, Germany, United Kingdom, Russian Federation, Poland, Romania, Ukraine
-
University Hospital, ToulouseCompletedIndolent Systemic Mastocytosis | Cutaneous MastocytosisFrance
-
University Hospital, ToulouseRecruitingMastocytosis, Indolent SystemicFrance
-
Allakos Inc.CompletedIndolent Systemic MastocytosisGermany
-
Cogent Biosciences, Inc.RecruitingMastocytosis | Mastocytosis, Systemic | SSM | Mastocytosis, IndolentUnited States, Italy, Canada, Australia, Spain, Switzerland, Norway, United Kingdom, Belgium, Poland, Netherlands, Germany, France, Czechia, Greece, Ireland
-
Blueprint Medicines CorporationAnalysis Group, Inc.CompletedMast Cell Leukemia | Aggressive Systemic Mastocytosis | Advanced Systemic Mastocytosis | Systemic Mastocytosis With an Associated Hematological NeoplasmUnited States, Austria, Germany, Spain, United Kingdom
-
National Heart, Lung, and Blood Institute (NHLBI)Completed